| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
WAY-624687 specifically targets glycogen synthase kinase 3 (GSK-3), a serine/threonine protein kinase that plays a critical role in the regulation of glycogen metabolism, cell proliferation, and apoptosis. By inhibiting GSK-3 activity, the compound modulates downstream signaling pathways including Wnt/β-catenin, PI3K/Akt, and NF-κB. GSK-3 inhibitors are studied for their potential in treating neurodegenerative diseases, diabetes, and cancer. The compound has a molecular formula of C₁₃H₉N₅S₂.
|
|---|---|
| ln Vitro |
In vitro, WAY-624687 functions as a GSK-3 inhibitor. Specific IC50 values for GSK-3 inhibition are not detailed in the available literature. As a research compound, its activity is typically assessed using kinase assays with recombinant GSK-3 enzyme and appropriate substrates. The compound may also be evaluated in cell-based assays to assess its effects on GSK-3 downstream targets such as β-catenin phosphorylation. The compound is soluble in DMSO at 10 mM.
|
| ln Vivo |
Specific in vivo data for WAY-624687 are not reported in the available literature. As a GSK-3 inhibitor, the compound would have potential for in vivo studies in models of neurodegenerative diseases (e.g., Alzheimer's disease), diabetes, and cancer. However, specific published in vivo protocols for this compound are not available. The compound is for research use only and not for human or veterinary use.
|
| Enzyme Assay |
The GSK-3 inhibitory activity is assessed using biochemical kinase assays. Recombinant GSK-3 enzyme is incubated with a peptide substrate and ATP in the presence of various concentrations of WAY-624687. The phosphorylation of the substrate is measured using a luminescent or fluorescent readout (e.g., ADP-Glo assay or Kinase-Glo assay). IC50 values are calculated from dose-response curves. Selectivity is assessed by profiling the compound against a panel of other kinases.
|
| Cell Assay |
For cellular studies, various cell lines (e.g., cancer cells, neuronal cells) are cultured in appropriate media. Cells are treated with WAY-624687 at various concentrations (e.g., 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or similar assays. GSK-3 activity is assessed by measuring phosphorylation of GSK-3 substrates (e.g., β-catenin, tau) by Western blot. The compound is typically dissolved in DMSO and diluted in culture media, with a final DMSO concentration ≤0.1%. The compound is soluble in DMSO at 10 mM.
|
| Animal Protocol |
In vivo studies for WAY-624687 would be conducted in appropriate animal models depending on the research focus. For neurodegenerative disease research, models such as transgenic Alzheimer's mouse models would be used. For diabetes research, diabetic or high-fat diet-induced obese models would be employed. For cancer research, xenograft models would be used. The compound would be administered via oral gavage or intraperitoneal injection. However, specific published protocols for this compound are not available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for WAY-624687 are not reported. The compound has a molecular weight of 299.37 g/mol and is soluble in DMSO at 10 mM. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, oral bioavailability, and tissue distribution in animal models. The compound should be stored as a powder at -20°C and protected from light.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for WAY-624687 are not reported in the available literature. As a research compound, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound is for research use only and not for human or veterinary use. Standard safety precautions should be taken when handling, and the compound should be used in a controlled laboratory environment.
|
| Additional Infomation |
WAY-624687 is a GSK-3 inhibitor for research use only. Molecular formula: C₁₃H₉N₅S₂, MW: 299.37. Soluble in DMSO at 10 mM. No clinical trials or regulatory approvals exist. For research use only, not for human or veterinary use.
|
| Molecular Formula |
C13H9N5S2
|
|---|---|
| Molecular Weight |
299.374058485031
|
| Exact Mass |
299.029
|
| CAS # |
753473-65-3
|
| PubChem CID |
3646030
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C(=NN2C(=NN=C2S1)C3=CC=NC=C3)C4=CC=CS4
|
| InChi Key |
VVZZLWGMXQRMPX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9N5S2/c1-2-11(19-7-1)10-8-20-13-16-15-12(18(13)17-10)9-3-5-14-6-4-9/h1-7H,8H2
|
| Chemical Name |
3-pyridin-4-yl-6-thiophen-2-yl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3403 mL | 16.7017 mL | 33.4035 mL | |
| 5 mM | 0.6681 mL | 3.3403 mL | 6.6807 mL | |
| 10 mM | 0.3340 mL | 1.6702 mL | 3.3403 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
